CFSAN on FDAAA Sec. 912
This article was originally published in The Tan Sheet
Executive Summary
FDA is reviewing comments that could shed light on the implementation of Sec. 912 of the Food and Drug Administration Amendments Act of 2007, but "we'll have to see what the new administration brings" before taking any action, says Louisa Nickerson, an attorney in the Department of Health and Human Services general counsel's office. At a Center for Food Safety and Applied Nutrition discussion of nutrition-related activities Dec. 12, Director Stephen Sundlof says the FDAAA provision "causes some problems for us" because it could make illegal any food substance originally evaluated, but not approved, as a drug. FDA's comment period has closed on how to implement Sec. 912 and a citizen petition that invoked the section in requesting FDA seize food products containing stevia-based sweeteners (1"The Tan Sheet" Nov. 3, 2008, p. 7)
You may also be interested in...
FDA Leaders’ Public Health Fundamentals Offer Hope To Sponsors
FDA wants to be judged on its overall impact on public health - not on drug approvals - Commissioner Peggy Hamburg and Principal Deputy Josh Sharfstein say in the New England Journal of Medicine
Stevia Nearing Sweet Taste Of Success, But Citizen Petition Could Spoil Party
Natural sweeteners derived from the stevia leaf appear mere months away from an international boom as a growing number of scientific and regulatory bodies approve the use of steviol glycosides in food and as major food and beverage players angle for a piece of the action
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”